EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Prevention of Stroke in Intracerebral Haemorrhage Survivors with Atrial Fibrillation: Rationale and Design for PRESTIGE-AF Trial

Eleni Korompoki, Peter Heuschmann, Kirsten H Harvey, Cornelia Fiessler, Uwe Malzahn, Klemens Hügen, Sabine Ullmann, Gabriele Putz Todd, Carolin Schuhmann, Joan Montaner, Igor Sibon, Stephanie Debette und 18 weitere

Thrombosis and Haemostasis · 01.04.2025 · 125 (04) · 395-403

DOI: 10.1055/a-2496-5492 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thrombosis and Haemostasis, erschienen am 01.04.2025. Verfasst von Eleni Korompoki und 29 weiteren Autor:innen. Beteiligte Einrichtung: Department of Brain Sciences, Imperial College London, London, United Kingdom. Hauptthemen laut MEDLINE: Anticoagulants, Atrial Fibrillation, Cerebral Hemorrhage, Factor Xa Inhibitors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Adequate secondary prevention in survivors of intracerebral hemorrhage (ICH) who also have atrial fibrillation (AF) is a long-standing clinical dilemma because these patients are at increased risk of recurrent ICH as well as of ischemic stroke. The efficacy and safety of oral anticoagulation, the standard preventive medication for ischemic stroke patients with AF, in ICH patients with AF are uncertain. PRESTIGE-AF is an international, phase 3b, multi-center, randomized, open, blinded end-point assessment (PROBE) clinical trial that compared the efficacy and safety of direct oral anticoagulants (DOACs) with no DOAC (either no antithrombotic treatment or any antiplatelet drug). Randomization occurred in a 1:1 ratio and stratification was based on ICH location and sex. The two co-primary binary endpoints included ischemic stroke and recurrent ICH which will be analyzed hierarchically according to the intention-to-treat principle. Secondary efficacy endpoints encompassed all-stroke and systemic embolism, all-cause and cardiovascular mortality, major adverse cardiac events, and net clinical benefit. Secondary safety endpoints included any major hemorrhage and intracranial hemorrhage. All outcome events were adjudicated by an independent committee. Results of PRESTIGE-AF are expected to support risk-adjusted secondary prevention in ICH survivors with AF and to inform clinical guideline recommendations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticoagulantsAtrial FibrillationCerebral HemorrhageFactor Xa InhibitorsSecondary PreventionStrokeAgedFemaleHumansMaleAdministration, OralClinical Trials, Phase III as TopicMulticenter Studies as TopicPlatelet Aggregation InhibitorsRandomized Controlled Trials as TopicRecurrenceRisk FactorsTreatment Outcome

Substanzen

AnticoagulantsFactor Xa InhibitorsPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Department of Brain Sciences, Imperial College London, London, United Kingdom.
  • Department of Clinical Therapeutics, National and Kapodistrian University of Athens, Alexandra Hospital, Athens, Greece.
  • Institute of Clinical Epidemiology and Biometry, University of Würzburg, Würzburg, Germany.
  • Clinical Trial Center Würzburg, University Hospital Würzburg, Würzburg, Germany.
  • Department of Neurology, Institute de Biomedicine of Seville, IBiS/Hospital Universitario Virgen del Rocío/CSIC/University of Seville, Hospital Universitario Virgen Macarena, Seville, Spain.
  • Neurovascular Research Laboratory, Vall d'Hebron Institute of Research (VHIR), Hospital Vall d'Hebron, Barcelona, Spain.

ORCID-Profile: Gregory Y H Lip, Deirdre A Lane

Zitieren

APA

Korompoki, E., Heuschmann, P., Harvey, K. H., Fiessler, C., Malzahn, U., Hügen, K., Ullmann, S., Todd, G. P., Schuhmann, C., Montaner, J., Sibon, I., Debette, S., Enzinger, C., Ropele, S., Rücker, V., Haas, K., Harvey, E., Wolfe, C., Wang, Y., …, & PRESTIGE-AF investigators (2025). Prevention of Stroke in Intracerebral Haemorrhage Survivors with Atrial Fibrillation: Rationale and Design for PRESTIGE-AF Trial. Thrombosis and Haemostasis, 125(04), 395-403. https://doi.org/10.1055/a-2496-5492

Vancouver

Korompoki E, Heuschmann P, Harvey KH, Fiessler C, Malzahn U, Hügen K, et al. Prevention of Stroke in Intracerebral Haemorrhage Survivors with Atrial Fibrillation: Rationale and Design for PRESTIGE-AF Trial. Thrombosis and Haemostasis. 2025;125(04):395-403. doi:10.1055/a-2496-5492

BibTeX
@article{Korompoki2025,
  author = {Korompoki, Eleni and Heuschmann, Peter and Harvey, Kirsten H and Fiessler, Cornelia and Malzahn, Uwe and Hügen, Klemens and Ullmann, Sabine and Todd, Gabriele Putz and Schuhmann, Carolin and Montaner, Joan and Sibon, Igor and Debette, Stephanie and Enzinger, Christian and Ropele, Stefan and Rücker, Viktoria and Haas, Kirsten and Harvey, Emily and Wolfe, Charles and Wang, Yanzhong and Nielsen, Peter B and Caso, Valeria and Lip, Gregory Y H and Lane, Deirdre A and Halse, Omid and Ringleb, Peter and Haefeli, Walter E and Foerster, Kathrin I and Wurmbach, Viktoria S and Veltkamp, Roland and PRESTIGE-AF investigators, PRESTIGE-AF investigators},
  title = {Prevention of Stroke in Intracerebral Haemorrhage Survivors with Atrial Fibrillation: Rationale and Design for PRESTIGE-AF Trial},
  journal = {Thrombosis and Haemostasis},
  year = {2025},
  volume = {125},
  number = {04},
  pages = {395--403},
  doi = {10.1055/a-2496-5492}
}
Kostenlos starten →